Good afternoon. Thank you for standing by. Welcome to the MiMedx First Quarter 2023 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Mr. Matt Notarianni, Head of Investor Relations for MiMedx. Thank you. You may begin.
Thank you, operator. Good afternoon, everyone. Welcome to the MiMedx First Quarter 2023 Operating and Financial Results Conference Call. With me on today's call are Chief Executive Officer, Joe Capper, and Chief Financial Officer, Pete Carlson. As part of today's webcast, we are simultaneously displaying slides that you can follow. You can access the slides from the investor relations website at mimedx.com. Joe will kick us off with some opening remarks. Pete will provide a summary of our operating highlights and financial results for the quarter. Joe will conclude with some additional updates, including a discussion of our financial goals. We will then be available for your questions.
Before we begin, I would like to remind you that our comments today will include forward-looking statements, including statements regarding future sales growth, future margins and expenses, expected market sizes for our products, and potential timelines for clinical trials and FDA submissions and reviews. These expectations are subject to risks and uncertainties, and actual results may differ materially from those anticipated due to many factors. Actual results, market sizes, timing, and FDA review will depend on a number of factors, including competition, access to customers, the reimbursement environment, unforeseen circumstances and delays, the results of our clinical trials, our interpretation of those results, and other factors. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our annual report on Form 10-K and our quarterly reports on Form 10-Q.
Our comments today include non-GAAP financial measures, and we provide a reconciliation to GAAP measures in our press release, which is available on our website at www.mimedx.com. With that, I'm now pleased to turn the call over to Joe Capper. Joe.
Thanks, Matt. Good afternoon, everyone. While it's only been two months since our last call, we have a lot of exciting news to share, starting with our outstanding first quarter performance, setting the stage for what we anticipate will be an extremely successful 2023. I've been on board now for a full quarter, and as I stated on our last call, this early assessment process continues to present a business that far surpasses my original expectations. During these first 90 days, I've spent time analyzing all parts of the business, formalizing our strategic planning process, meeting with customers, business partners, and several of you in the shareholder community, all in an effort to determine our best path forward. While still early on, it's becoming clear to me that we operate in a relatively less orderly area of the healthcare industry, which is abundant in untapped opportunities.
I will discuss in more detail our plan to ensure the company capitalizes on these many opportunities while continuing to optimize our operating platform. First, I want to hit on some of the most noteworthy highlights from the first quarter. Q1 year-over-year net sales grew by nearly 22% to $71.7 million, the highest first quarter net sales performance we have delivered in five years. Gross profit margin is 82.7%, which was an improvement sequentially. Adjusted EBITDA was $5.5 million, up from a loss of $1.7 million a year ago, a $7.2 million swing in the right direction. These positive results all reflect superb execution on the part of the entire company. Among these impressive numbers, our adjusted EBITDA warrants special attention.
To be able to generate $5.5 million of positive adjusted EBITDA so early in the year clearly shows that we are beginning to unlock leverage in the business, which will undoubtedly improve with scale. We have no interest in revenue just for the sake of growing. We must, and will, improve our profitability as we grow. Naturally, this will increase free cash flow generation, our balance sheet will improve, and we will create growth funding optionality. Our better-than-expected performance becomes that much more impressive when you consider that our expense burden in Q1 is typically higher than other quarters during the year. Specifically, we had about $3 million of expense during the quarter as a result of payroll taxes reset in January first and the cost of our national sales meeting, both of which will not recur for the remainder of the year.
These expenses and the annual bonus payout were uses of cash specific to the first quarter. As such, we expect to build cash as we move further into the year. Pete will unpack the numbers in more detail, but suffice it to say, we could not be more excited about this great start to the year. Our best-in-class products, highly skilled team, and improving financial profile give me tremendous confidence in our ability to create significant value as we take MiMedx to new heights. It is my practice on earnings calls to report the company's progress as it relates to the key elements of our strategic focus.
On our last call, I spoke about the three areas in which we are concentrating our time and resources in order to drive growth and sustain value creation. As a reminder, our first growth objective is to build on our leadership position in the Wound & Surgical markets by enhancing our product portfolio and expanding geographically. Success in achieving this objective will be dictated by how well our commercial organization performs over time. This first quarter was certainly an example of what commercial excellence looks like. To that end, during the quarter, we achieved year-over-year revenue growth across all sites of service. We had a welcome sales increase in the private office segment. You may recall that this has been a particularly challenging area for us given the current Medicare reimbursement environment, which creates an opportunity for certain companies to manipulate the system.
During the quarter, the OIG published a report relating to the reimbursement practices we have repeatedly raised as concern. While the OIG report is clearly aligned with our position, it is premature to determine if and when these practices will be reined in. We continue to stay close to the rulemaking process and remain optimistic it will result in a level playing field. In the surgical recovery segment, we continued to build momentum, particularly around our new products, which were launched in the second part of last year. We believe the future for growing our footprint across a variety of surgical procedures remains bright, particularly as the body of real-world evidence for a wide range of applications continues to grow. Finally, we made more headway developing our business in Japan, with initial sales starting to come in from this important international market.
We anticipate adoption to begin to ramp in the coming months and quarters. Our second growth objective is to develop opportunities in adjacent markets to create additional growth drivers for the company. Think about this as a means to, first and foremost, strengthen our position in the market segments in which we currently compete by broadening our offering.
As such, we have formalized a process for assessing and prioritizing various strategic opportunities as they arise. Additionally, we will look for ways to leverage our technology and commercial strength in order to develop adjacent opportunities, with the Knee OA project representing our major investment. To that end, we were excited to get the Knee OA study officially up and running and to begin enrolling patients during the quarter.
As a reminder, in this first of two required studies, we expect enrollment of approximately 470 patients with three arms, a six month observation period, and six additional months of monitoring. We will continue to report on the project as we achieve critical milestones or have newsworthy information to share. Finally, our third objective is to build a corporate discipline around expense management, rationalization, and continuous process improvement in order to ensure our growth becomes more profitable over time.
As the Q1 results indicate, this approach is already beginning to take shape within the organization. Our efforts to enhance efficiencies and production yields and operations resulted in a sequential improvement in gross margin. I anticipate that the team will continue to execute on our plan, resulting in further margin improvement and enhanced ability to scale over time.
Additionally, the Wound & Surgical contribution margin improved to 28.5% in Q1. As you will recall, our goal is to get to 30%, and we are well on our way. Another efficiency metric we've spoken about is to get our corporate expenses as a percent of our net sales to 20% or below. For Q1, this number improved to 20.4% as a result of efforts to curb G&A across the enterprise. All in all, the team did an excellent job building on the momentum we had coming out last year. Our formula for success lies in our ability to consistently identify and execute against the most relevant growth drivers for our business.
As I mentioned on our last call, if we remain focused and execute on the plan I just outlined, I'm confident we will continue to build on this franchise, have the opportunity to create tremendous value, and once again establish MiMedx as a world-class healthcare company. Let me turn the call over to Pete, who will recap our first quarter results. Pete?
Thank you, Joe. Good afternoon, everyone, and thanks for joining us today. Before I begin my remarks about the first quarter, I want to reflect on my time with MiMedx as I prepare to move on to future opportunities and how it has been a pleasure serving as MiMedx's CFO these last several years. I am proud of the team's progress since I joined, and I'm honored to have helped lead an organization with products that impact the lives of a large and growing number of patients. In addition to continuing to expand access to our products over the last three years, we've also built a robust finance and accounting organization that is positioned to deliver as the business scales in the future. I thank the team for all the efforts. Moving on now to our first quarter.
As a reminder, unless otherwise specified, all results referenced in my prepared remarks are on a first quarter 2023 versus first quarter 2022 comparison basis. First, as Joe mentioned, our first quarter 2023 net sales were $71.7 million compared to $58.9 million. Joe outlines many of the specific drivers of this performance in his remarks, and I'm pleased to also report on the numerous areas of strength we saw to start the year. On a sequential basis, while our first quarter is historically the lowest revenue quarter of the year due to deductible resets and generally lower patient traffic, our first quarter net sales figure represents the smallest step down from the preceding fourth quarter that we have seen in recent years.
You may recall that in the first quarter of 2022, we were faced with challenges associated with the Omicron wave of COVID-19, which we did not have to deal with in the first quarter of 2023. Our first quarter results benefited, albeit modestly, from one additional shipping day compared to the first quarter of 2022. Looking ahead over the next three quarters, we have one fewer shipping day in Q2, one fewer shipping day in Q3, and the same number of shipping days in Q4 compared to each of these periods in 2022. Moving to gross profit and gross margins. Our first quarter gross profit was $59.3 million compared to $49 million, and our gross margin was 82.7% compared to 83.1%, roughly flat on a year-over-year basis.
On a sequential basis, the improvement in our gross margin reverses a several quarter trend that saw pressure from lower production yields weigh in our performance. While there are several factors impacting gross margin, including product mix, I want to highlight the efforts of our quality, operations and regulatory teams in improving our production efficiency. As you know, this has been a major focus for us in 2023, and we continue to think the business is capable of delivering gross margin % in the mid-80s over the long term. Selling, general and administrative expenses or SG&A were $52.3 million compared to $49.6 million.
The increase was primarily driven by higher sales along with higher travel expenses in the first quarter, both of which more than offset savings associated with actions taken in the fourth quarter of 2022 related to headcount. Our research and development expenses were $6.5 million compared to $6 million. The increase over the prior year period was driven primarily by costs associated with the start of our Knee OA trial in the first quarter.
Investigation, restatement and related expenses were $3.7 million compared to $2.6 million. Based on a recent filing with the court, it appears the long-running SEC civil matter against the company's former CFO is nearing a resolution.
Once this resolution is finalized, we anticipate the costs associated with that matter to cease and the costs included in this category to decrease materially in the near term. We may continue to incur legal expenses resulting from the investigation, but this matter with the SEC would conclude a sizable expense burden the company has shouldered over the past several years.
Net loss was $5 million compared to a net loss of $10.5 million. Adjusted EBITDA was income of $5.5 million or 7.7% of net sales, compared to a loss of $1.7 million or negative 2.9% of net sales. On a segment basis, net sales in Wound & Surgical totaled $70.6 million compared to $58.3 million, reflecting growth of approximately 21%.
The Wound & Surgical segment contribution of $20.1 million represented 28.5% of Wound & Surgical net sales, compared to a segment contribution of $13.2 million, which represented 22.6% of Wound & Surgical net sales during the first quarter of 2022. Turning to Regenerative Medicine. Operating expenses totaled $5 million compared to $4 million.
This increase was driven by the commencement of our Knee OA clinical trial, which began recruiting, screening and enrolling patients during the quarter. We expect spending to continue to ramp through the year as additional sites come online and patient enrollment activity increases.
Finally, our SG&A expenses in Corporate & Other totaled $14.6 million, representing 20.4% of our total net sales, compared to $15.5 million, which represented 26.4% of total net sales. Excluding stock compensation, our Corporate & Other SG&A expenses totaled $12.1 million, representing 16.9% of our total net sales, compared to $13.6 million, which represented 23% of total net sales in the first quarter of 2022. As of 31st March , 2023, the company had $61.2 million of cash and cash equivalents compared to $66 million as of 31st December , 2022.
The sequential decline in our cash and cash equivalents was driven by several factors that typically hit in the first quarter, such as the payment of annual employee incentive compensation, as well as investments in working capital, primarily accounts receivable and inventory that reflect increased sales activity. Based upon our current position and expectations for the business, I want to reemphasize that we would remain well capitalized and do not foresee the need for external financing.
I will now turn the call back to Joe. Joe?
Thanks, Pete. As you know, Pete will be leaving MiMedx in the coming months. I would like to take this opportunity to recognize and thank Pete for the incredible work he has done during his time with MiMedx. Pete joined at a pivotal point in the company's history, when it needed to make vital changes to strengthen our accounting and finance organization. Pete did an outstanding job, and the company is on solid financial footing thanks to his leadership and experience. He leaves behind a strong team and a lengthy list of accomplishments.
We are grateful for all that Pete has contributed to MiMedx and wish him our sincere best in all future endeavors. The search for our next CFO is ongoing, and we look forward to bringing in an individual of similar caliber in the coming months.
Pete will continue to work with the company to ensure that a smooth and seamless transition takes place. In summary, as you have just heard, we started the year with an excellent first quarter, during which we recorded quarterly revenue of $71.7 million, up nearly 22% year-over-year. Gross profit margin of 82.7%. Adjusted EBITDA of $5.5 million.
Continued to roll out of our new products in the U.S. began selling product in Japan, and continued to drive efficiency and expense rationalization throughout the organization. Pete just spoke about our cash position and the fact that we do not foresee the need for an additional capital raise in order to fund our current business plan short of any meaningful investment opportunities. To add a bit more color, two additional developments are worth mentioning.
First, you will recall our previously announced $10 million commitment to Turn Therapeutics contingent upon 510(k) FDA clearance for their FleX product. However, this milestone was not met, and we no longer expect to make the payment this year. Second, as Pete mentioned, we believe we are nearing the end of a portion of legal expense overhang related to past issues, which has not been insignificant. With the conclusion of such matters in our sight, we look forward to a more productive use of capital. Looking ahead, we expect to build cash from this point forward.
I'll close by stating that while one quarter does not represent a trend, I believe our business is in an exciting phase of growth as we seek to combine commercial success with operational excellence in pursuit of sustainable, profitable growth, and as a result, a very bright future.
With all that I have learned since joining MiMedx, I am confident we can do just that. Given our strong start to the year, I want to reiterate our expectation for low double-digit top-line growth for the foreseeable future. With that, I'd like to open the call to questions. Operator, we are now ready for our first question. Please proceed.
Thank you. At this time, we will be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we poll for questions. Our first question comes from the line of Anthony Petrone with Mizuho Securities. Please proceed with your question.
Oh, great. Congratulations on the strong quarter here. Pete, good luck on the transition. It was great working together and hope to see you again soon. You know, maybe to start just on, you know, the top-line performance in the quarter, certainly ahead of our expectations. Joe and Pete, we've been hearing a lot this earnings season so far about a procedure volume rebound on several of the earnings calls over the past two weeks.
That was showing up in our data earlier in the quarter. Then in, again, in some of the results we've seen, it's pretty evident that, you know, things sort of changed this quarter when we think about throughput capacity and generally speaking, patients coming back into the system.
When we think of the surgical end channel, first, you know, how much of what we saw in the quarter was easy comps, you know, versus patients coming back into the system? I would even second that for the physician office channel. How much of it was easy comps versus we're finally getting back to a more normalized patient flow dynamics in that channel as well? Then I'll have a couple of follow-ups. Thanks.
Why don't you start, Pete?
Good afternoon, Anthony, and thanks for those comments, as well as the questions. When we look at it overall, I would say, you know, probably as much as 5% of our growth is driven by the combination of the easier comp last year due to the COVID impact that we talked about as well as the extra day. That is driving some of the growth.
You know, we knew that was gonna be a factor, obviously, both of those items. As you saw, well, may not have had a chance to see, but in our 10-Q, you can see that we had growth in both of those channels you mentioned. In the hospital, the growth is 17%-ish, in the private office, it's over 30%.
There are multiple factors beyond just the easier compare a year ago and the extra day. We have seen volumes up. As Joe said in his prepared remarks, we saw it across really all care settings. The team has really been executing well.
We do think there is, I would say, a trend of not only the additional patient volume, but some aspect of practices, you know, working with us, where maybe they hadn't been recently because of the reimbursement environment, and so they were making more economic decisions. That one's really hard to quantify. Then we did, and you see this principally in the surgical area, and that's reflected in some of that hospital growth. Our new products are key contributor to the growth overall.
We're very pleased with how those are performing. All of those factors are drivers for the top line growth you see, which did exceed not only your expectations that you mentioned, but even some of our internal expectations. I think your comment about patient volume is an appropriate comment. We've seen the same reports, you know, across the spectrum of just higher volumes. Yeah, Joe, anything you'd add?
Just a little bit more, Anthony. First of all, thanks for the question. You know, in preparing for today's call, we spent a good bit of time on this trying to bifurcate how much of it was market driven, how much of it was just pure execution, right? 'Cause we wanna get the right tone and message across. What Pete just talked about was kind of the dynamics in the market and we did see upticks in all the sites of service. I think it's important to kind of give a little bit of color about the quarter itself. Each month in the quarter was significantly better than each month in the prior year.
Each month in the quarter, while there's only three, built on the previous month, to the point where in March, we saw a sales number that frankly, we didn't see till very late last year. The team is executing much better. A good portion of that growth did come from, you know, a superior quarterly performance, a superior execution. I said, you know, one quarter doesn't make a trend, so time will tell. If you continue to see above market growth rates for the rest of the year, it'll tell you that the organization is just performing better than our comps.
No, very helpful color there. I guess, you know, a logical follow-up is just, you know, when you think of a +21.7% performance and what appears like, at least to some degree, some sustainable drivers over the next few quarters. Joe, you reiterate the low double digit sort of long-term growth rate, but to push you a little bit here, I mean, you know, not to get ahead of ourselves, but, you know, is it possible that you certainly trend above that long range target for the remainder of 2023?
Well, first, I'm glad that you picked up on that. Yeah, part of that, Anthony, is because the first quarter does have noise in it, you know, given that last year's Q1 was slightly different, we gotta give it a little bit more time to see what's really there. I do like the momentum coming out of the fourth quarter. I like the momentum we saw in the first quarter.
It's still very early for me. I've been here for a whopping 90 days, so I'm still getting the feel for the rhythm of this business, the ebbs and flows of the business. It's just gonna take me a little bit more time, right? I think Q1, or excuse me, Q2, Q3 will tell that story.
I'd hate to get way out ahead of ourselves, as you indicate, and, you know, start pounding our chest and say everything's great, 'cause you always have challenges and there's still, I think, some things that have to shake out in the private office that before we really know what's happening there. I like it. I really like it in that kind of low double-digit area, you know. You know, look, it's not us trying to sandbag, seriously. We're just trying to give you our realistic expectation for the full year.
No, understood. Last one for me, and I'll get in queue here, is the $5.5 million in adjusted EBITDA, also well ahead of expectations. Maybe just to close out here, I mean, how much of that was purely the revenue beat versus some of the restructuring activities that are ongoing? Again, congratulations on the quarter and thanks for taking our questions.
Thanks.
Thanks, Anthony. You know, the adjusted EBITDA number has multiple components to it. Certainly sales volume is positive with the high gross margins. As we noted, the gross margins in the quarter were also up on a sequential basis, relatively flat to a year-ago. From getting our gross margins back up, approaching the mid-80s, and we think we can get to the mid-80s, you know, within the next 12- 15 months or so, that's very helpful to our bottom line performance. We also did have efficiencies and leverage. We know there's leverage in the system here. We're very pleased to see the SG&A cost grow at such a much lower level than the revenue grew in the quarter.
You know, we've always said is we get our revenue growing that you would not need to model out expenses growing at the same level. Certainly, the activities, and some of the actions we took in the fourth quarter contributed. Again, just in some of the personnel moves we made at that VP and higher level have a $5 million annual run rate. You're seeing a, you know, a $1 million plus of that running through here in the first quarter. All of those factors are good. Being cautious on expenses, both in the G&A level and in the selling level, and then, gross margin improvements. The team's done a great job there. It is process and efficiency matters, and there's more to come.
Obviously, at 80%+ margins, a good bit of that falls to the bottom line when you have strong quarter like we did in revenue.
Thank you again.
Our next question comes from the line of Carl Byrnes with Northland Securities. Please proceed with your question.
Thanks for the question and congratulations on the strong quarter. Pete, thanks for all your help. I think most of my questions have been addressed here, but I wanted to drill it down a little bit more on the physician segment being up 30%. Obviously, you know, there was pent-up demand, and you're seeing some of that work off mid-COVID and the extra day. Were there any other factors that you attribute to that 30% gain? More specifically, I mean, do you think the OIG recommendation to CMS would have had any effect in terms of private practices, you know, avoiding products that wouldn't fit the recommendation in your favor? Thanks.
Yeah, I think so. There's two things that really happened. One, there was a call that CMS hosted in January, early in the quarter. That could have caused a slight change in behavior because it brought more attention to it, and they talked about potential areas that they can move. Then late in the quarter, we had the OIG letter, which certainly probably helped somewhat.
How much? Again, we don't know yet. That's why we're a little bit cautious about, you know, the expectations going forward, because I think it's going to take a little bit of time for this to settle out. Yeah, that probably had somewhat of an impact.
Great. Thanks.
Our next question comes from the line of, Swayam pakula with H.C. Wainwright. Please proceed with your question.
Thank you. Thanks for taking my questions. Pete, I wish you the best, and it's nothing like leaving on a high note. Good luck and talk to you soon. Just to follow up on Anthony's line of questioning, you know, one of the things you folks have been talking to us this afternoon is on execution and how good the execution has been. Part of that execution formula is the sales force being with you for a longer period, right? As the experience increases, they're going to get better and better. Can you just talk to that effect?
I know, I think about couple of years ago, you know, there were some new, some addition to their sales force, and I'm just trying to figure out how much of that is helping out because that can potentially provide some sustenance.
I think it's helping a lot. I think the sales force leadership that was put in place a few years back, had to make a lot of changes, to bring order to the organization, and I think they did a great job with that. I'm extremely pleased with, not just the leadership but the performance of the sales organization. To your point, when you settle down, turn over a little bit, you have a bit more stability.
When you have good, clear direction, you have better performance as well. I think all the above, RK. I think the team is doing a very good job. I expect that as we grow this business, as Pete indicated, you will see more leverage out of the S in SG&A.
Clearly, you're going to get more leverage out of G&A because we have more control over that. I think the organization did a good job of streamlining and cleaning a bit of that up, as Pete indicated, and we're starting to reap the benefit of that.
My expectation is we'll see EBITDA improvement along the way. Where it goes, I'm not quite sure yet because we're not there, and we don't know what it's going to take to get there. I fully anticipate EBITDA margin improvement as this business scales. A good bit of it will come through by leveraging that sales organization.
Okay, fantastic. Thanks for that. Then, talking about patient volumes. So, what are the metrics that you folks follow on the patient volumes and how you know, do you see that consistently increasing into the second quarter as well? We are about a month and a half into it now. I'm trying to think about how we could think about at least for the second quarter, because that was also, you know, when you compare it with again second quarter of 2022, that is still a lighter quarter for you folks over the full year last year.
The, the first one, you were talking about patient metrics, and I'm not sure that's something that we've traditionally put out. Then the second part of your question was really around, Q2. I'm sorry, you were breaking up a little bit.
Yes.
you said Q2. look, right now.
Yes.
What's that?
You're right. It was it was Q2.
Yeah. We, you know, right now we're really kind of sticking to kind of annual guidance of that low double-digit, there will be some movement quarter to quarter. You know, RK, I'm gonna cop out on that one and say I need more time to figure out the rhythm of this business, frankly.
Well, I'll tell you, we're doing everything we can to grow this business, we have new products in the pipeline. It's not just sales force execution, but we see that continuing to improve. We have Japan starting to come online. We have drivers in the business that will help us grow, but we're just not comfortable yet saying that, you know... We're certainly not comfortable giving quarterly guidance at this juncture.
RK, it's Pete. Just going back to last year, you mentioned some of the quarterly swing there. You know, one of the things nobody really can put a handle on is this vacation impact that hit the third quarter harder than people expected last year. Is that now a recurring trend, just like so many of these other things? Are we in a new normal or not? We have no idea on that. That's hard to predict from that standpoint.
Thank you. One last question from me. On the new product contribution, is there any additional color that you can provide on that? Obviously, as Japan matures, that will be a major contributor, as you just said.
RK, it's Pete. You know, the new products have been successful. We're really pleased with those. They were a good contributor in the fourth quarter and continued that contribution here in the first quarter. They are a big driver of year-over-year growth. Remember, we've got two of them out there. One's a particulate and one's a sheet product that has some unique characteristics, different than other products we have in the portfolio.
The other is that comparison year-over-year starts to run out as we get into September. It's a big driver here in first and second quarter of year-over-year growth, but then it becomes less as you get to third quarter and obviously fourth quarter. We're very pleased. It's really helping our surgical recovery strategy, and it's a variety of procedures.
Frankly, we see that expanding as time goes on. Both the number of clinics or hospitals using and physicians using the product, as well as the nature of procedures being used. It's one of these things that as we have more and more case studies from actual applications, we can share those stories and it really builds on itself.
We've made an investment in medical education and a concentrated effort there, and that's one of the ways we get that information out. We get, you know, people, doctors, practitioners who have credibility and can share stories, talking across the footprint, and that can really help the team. We're very pleased with it. It's the two different types of products.
It ties into the surgical recovery strategy, and the real world evidence, the case evidence is gonna be a strong driver because surgeons are. You know, that's an area that has a high bar for data, if you will, and this is the way we get data.
You're exactly right. It's the it drove surgical recovery, drove the 78% growth. You're right. In order to continue to see growth there, we're going to need to continue to invest in research because they want data.
Fantastic. Thank you both, and, congratulations again on a great quarter.
Thanks, RK.
Our next question comes from the line of John Vandermosten with Zacks. Please proceed with your question.
Thank you. Joe and Pete, thank you for taking my question. Thought I'd start out with a question on new products. You said that was one of the big drivers for performance in the first quarter. I know that there had been a goal to, you know, roll out some new products every year to kinda keep that going on. How is that coming along for 2023? Then I think you had mentioned something about Turn Therapeutics and perhaps that milestone had been delayed. Will that be related to one of the new products, and how will that kind of fold into that goal of new product launch?
Yeah. Yeah. Just the kind of commitment within the organization was to try to get two to market each year. We're not tied to that number. It doesn't have to be two, but it's not a bad guidepost because this market does require innovation to stay relevant.
It's an area that we continue to invest, and we have a fairly robust pipeline of opportunities to continue to introduce to the market in the coming years. Turn clearly was one of those that would've introduced an antimicrobial xenograft into our portfolio. Would have been a first. It would have been a 510(k) approval, which would have been a predicate for us to build upon. Unfortunately, the 510(k) milestone was not met. We continue to work with them.
We continue to think that the antimicrobial is the right way to go. We'll see how that unfolds. You're right, we, the milestone was missed contractually. We're not committed to make that payment this calendar year. That, but that will need to be renegotiated.
John Vandermosten, it's Pete Carlson. That was in our sights as a new product for the year. A reminder that we have access to that antimicrobial technology without this specific product approval. There are really two parts to that transaction. We are doing work there, whether we get something out this year or very soon next year. We're working actively with this antimicrobial technology and think it can be very helpful in generating those new products. As Joe Capper said, it's a spirit of new product development. The goal was putting a number on something that hadn't happened for a while, and it was really a mindset reshift for the company as much as externally.
We were really trying to get make sure the focus across the company was on product development, and we've been successful in that, and we will reap those rewards as we go forward.
Okay, thanks. Again, on the kind of the looking forward to revenue growth and Japan, you know, I sense that, you know, probably it's still early days and they're not substantially material yet, the revenue contribution, I mean. How do you expect that to evolve over the year? I know you had been training a bunch of providers. Is that still going strong, that training exercise?
It is. We have some of our own folks on the ground there as well. Not a lot, but we have a network of physicians that have been trained, several hundred, and we're starting to see the product used in procedures, so it's being pulled through from our partner in Japan. We expect the market to develop nicely, it's slow, right?
There's a lot of missionary work that needs to be done in these early days. The fact that we have some sales already is very heartening, and we anticipate in the coming months, the coming quarters, that will begin to build. Again, a little early to put numbers on it, but we're very optimistic about how the product is starting to unfold.
Okay, great. Thank you, Joe. Thank you, Pete.
Yep.
As a reminder, if you have any questions, you may press star one on your telephone keypad. Doing so will ensure that you are joined into the que.